Login to Your Account

Other News To Note

Thursday, July 14, 2011
OncoVista Innovative Therapies Inc., of San Antonio, initiated a preclinical safety study of OVI-117, an L-Nucleoside conjugate for solid tumors, in a second animal species. The company also is preparing to submit an investigational new drug application and plans to begin Phase I trials by the end of the year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription